Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
9.42
-0.11 (-1.10%)
At close: Jan 22, 2026, 4:00 PM EST
9.39
-0.02 (-0.27%)
After-hours: Jan 22, 2026, 5:50 PM EST
Anika Therapeutics Revenue
Anika Therapeutics had revenue of $27.82M in the quarter ending September 30, 2025, a decrease of -5.89%. This brings the company's revenue in the last twelve months to $112.81M, down -14.72% year-over-year. In the year 2024, Anika Therapeutics had annual revenue of $119.91M, down -0.73%.
Revenue (ttm)
$112.81M
Revenue Growth
-14.72%
P/S Ratio
1.20
Revenue / Employee
$391,688
Employees
288
Market Cap
135.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.91M | -885.00K | -0.73% |
| Dec 31, 2023 | 120.79M | 6.97M | 6.12% |
| Dec 31, 2022 | 113.83M | -33.97M | -22.98% |
| Dec 31, 2021 | 147.79M | 17.34M | 13.29% |
| Dec 31, 2020 | 130.46M | 15.85M | 13.83% |
| Dec 31, 2019 | 114.61M | 9.06M | 8.58% |
| Dec 31, 2018 | 105.56M | -7.87M | -6.93% |
| Dec 31, 2017 | 113.42M | 10.04M | 9.71% |
| Dec 31, 2016 | 103.38M | 10.38M | 11.16% |
| Dec 31, 2015 | 93.00M | -12.60M | -11.93% |
| Dec 31, 2014 | 105.60M | 30.51M | 40.64% |
| Dec 31, 2013 | 75.08M | 3.72M | 5.22% |
| Dec 31, 2012 | 71.36M | 6.58M | 10.16% |
| Dec 31, 2011 | 64.78M | 9.22M | 16.60% |
| Dec 31, 2010 | 55.56M | 15.42M | 38.42% |
| Dec 31, 2009 | 40.14M | 4.36M | 12.17% |
| Dec 31, 2008 | 35.78M | 4.95M | 16.06% |
| Dec 31, 2007 | 30.83M | 3.99M | 14.86% |
| Dec 31, 2006 | 26.84M | -2.99M | -10.04% |
| Dec 31, 2005 | 29.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evolus | 285.82M |
| Aurora Cannabis | 263.57M |
| Organigram Global | 186.08M |
| Assertio Holdings | 137.35M |
| Lifecore Biomedical | 128.87M |
| Journey Medical | 59.40M |
| Cumberland Pharmaceuticals | 41.28M |
| Alpha Teknova | 39.80M |
ANIK News
- 2 months ago - Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Anika Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025 - GlobeNewsWire
- 3 months ago - ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders - GlobeNewsWire
- 4 months ago - Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 months ago - Anika Therapeutics: Undervalued HA Platform With 2027 Catalysts - Seeking Alpha
- 6 months ago - Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Anika Reports Second Quarter 2025 Financial Results - GlobeNewsWire